The Strategist

Reckitt Benckiser gets $ 1.4 bln fine in the US for advertising opioid dependence drug

07/12/2019 - 10:13

Reckitt Benckiser Corporation will pay $ 1.4 billion to settle charges of the US authorities in connection with the sale of Suboxone drug, which allegedly cured opioid dependence better than other drugs.

Reckitt Benckiser gets $ 1.4 bln fine in the US for advertising opioid dependence drug
The US Department of Justice called the fine "the largest reimbursement for opioid drugs in American history."

At the same time, the officials once again noted that "the United States is experiencing the most deadly opioid crisis in its history," while drug manufacturers are taking advantage of those people who are dependent on opioid drugs.

A $ 1.4 billion fine was brought against Reckitt Benckiser under the accusations leveled by US authorities in April 2019 against Indivior. Until December 2014, the latter was a subsidiary of Reckitt Benckiser. Indivior has positioned Suboxone Film, a drug containing buprenorphine and naloxone, as a safer drug for treating opioid dependence than other drugs.

Reckitt Benckiser stated that "they deny all allegations of misconduct," but the board of directors of the company decided that paying this amount to settle the charge "is in the best interests of the company and the shareholders."

This is not the first penalty in respect to pharmaceutical companies - and, most likely, will not be the last in the current opioid crisis that has been going on in the United States in recent years. In April 2019, Rochester Drug Cooperative was fined for illegal distribution of oxycodone and fentanyl, a synthetic opioid.


< >

Monday, September 25th 2023 - 03:49 EC re-fines Intel over violations in PC chip market